IDH inhibitors and the evolving AML treatment paradigm

preview_player
Показать описание
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, reflects on the evolving treatment paradigm of acute myeloid leukemia (AML), highlighting the role of IDH inhibitors in various populations of AML. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Stéphane de Botton
  3. Institution: Gustave Roussy Institute
  4. Event: ASCO 2022
  5. Format: Interview
  6. Subject: Leukemia
Рекомендации по теме
IDH inhibitors and 0:00:54

IDH inhibitors and the evolving AML treatment paradigm

Paresh Vyas | 0:01:15

Paresh Vyas | ISAL 2019 | Clonal evolution under IDH inhibitor treatment in patients with AML

Acute Myeloid Leukemia: 0:52:20

Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways

IDH Inhibitors for 0:02:05

IDH Inhibitors for Cholangiocarcinoma

IDH inhibitors for 0:01:32

IDH inhibitors for AML and MDS

Why Early Transplant 0:00:21

Why Early Transplant Consideration is Crucial for AML Treatment

The promising role 0:01:53

The promising role of IDH inhibitors in AML

How New Targeted 0:02:26

How New Targeted Therapies Are Changing Frontline AML Treatment – Dr. Elias Jabbour

How the AML 0:03:40

How the AML treatment landscape has evolved with the use of novel combination therapies

IDH Inhibitors for 0:08:50

IDH Inhibitors for AML

The prognostic impact 0:02:53

The prognostic impact of IDH mutations and the role of IDH inhibitors in MDS

Advances Changing the 0:02:18

Advances Changing the Treatment Landscape of AML

AML Immunotherapy Struggle: 0:00:17

AML Immunotherapy Struggle: Why Targeting Cancer Cells Is So Hard!

IDH1/2 inhibitors for 0:01:51

IDH1/2 inhibitors for upfront AML therapy and transfusion independence

Emerging Targeted Agents 0:04:26

Emerging Targeted Agents in AML

Evolution of the 0:02:58

Evolution of the AML treatment paradigm

IDH inhibitors in 0:42:38

IDH inhibitors in relapsed/refractory AML

Clonal Heterogeneity and 1:02:18

Clonal Heterogeneity and Evolution in AML

Dr. Ross Levine 0:37:15

Dr. Ross Levine on deciphering and targeting clonal evolution in myeloid malignancies

IDH1/2 inhibitors for 0:06:41

IDH1/2 inhibitors for AML

IDH inhibitors in 0:00:59

IDH inhibitors in AML

Novel Agents Targeting 0:10:12

Novel Agents Targeting Diffuse Astrocytoma

Emerging FLT3 Inhibitors 0:05:49

Emerging FLT3 Inhibitors in AML

Dr. McCloskey Discusses 0:02:15

Dr. McCloskey Discusses IDH Inhibitors in AML

visit shbcf.ru